Literature DB >> 12948018

Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.

Matthew D Troutman1, Dhiren R Thakker.   

Abstract

PURPOSE: The purpose of this work was to determine whether P-glycoprotein (P-gp) modulates absorptive and secretory transport equally across polarized epithelium (i.e., Caco-2 cell monolayers) for structurally diverse P-gp substrates, a requirement for the use of the efflux ratio to quantify P-gp-mediated attenuation of absorption across intestinal epithelium.
METHODS: Studies were performed in Caco-2 cell monolayers. Apparent permeability (P(app)) in absorptive (P(app,AB)) and secretory (P(app,BA)) directions as well as efflux ratios (P(app,BA)/P(app,AB)) were determined for substrates as a function of concentration. Transport of these compounds (10 microM) was measured under normal conditions and in the presence of the P-gp inhibitor, GW918 (1 microM), to dissect the effect of P-gp on absorptive and secretory transport. Apparent biochemical constants of P-gp-mediated efflux activity were calculated for both transport directions.
RESULTS: Efflux ratios for rhodamine 123 and digoxin were comparable (approx. 10). However, transport studies in the presence of GW918 revealed that P-gp attenuated absorptive transport of digoxin by approx. 8-fold but had no effect on absorptive transport of rhodamine 123 (presumably because absorptive transport of rhodamine 123 occurs via paracellular route). The apparent Km for P-gp-mediated efflux of digoxin was > 6-fold larger in absorptive vs. secretory direction. For structurally diverse P-gp substrates (acebutolol, colchicine, digoxin, etoposide, methylprednisolone, prednisolone, quinidine, and talinolol) apparent Km was approximately 3 to 8-fold greater in absorptive vs. secretory transport direction, whereas apparent J(max) was somewhat similar in both transport directions.
CONCLUSIONS: P-gp-mediated efflux activity observed during absorptive and secretory transport was asymmetric for all substrates tested. For substrates that crossed polarized epithelium via transcellular pathway in both directions, this difference appears to be caused by greater apparent Km of P-gp-mediated efflux activity in absorptive vs. secretory direction. These results clearly suggest that use of efflux ratios could be misleading in predicting the extent to which P-gp attenuates the absorptive transport of substrates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12948018     DOI: 10.1023/a:1025049014674

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  48 in total

1.  Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

Authors:  R B Kim; C Wandel; B Leake; M Cvetkovic; M F Fromm; P J Dempsey; M M Roden; F Belas; A K Chaudhary; D M Roden; A J Wood; G R Wilkinson
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

Review 2.  Pharmacological insights from P-glycoprotein knockout mice.

Authors:  A H Schinkel
Journal:  Int J Clin Pharmacol Ther       Date:  1998-01       Impact factor: 1.366

Review 3.  Drug exsorption from blood into the gastrointestinal tract.

Authors:  K Arimori; M Nakano
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

4.  Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers.

Authors:  K Lee; D R Thakker
Journal:  J Pharm Sci       Date:  1999-07       Impact factor: 3.534

5.  Digoxin interactions. The influence of quinidine and verapamil on the pharmacokinetics and receptor binding of digitalis glycosides.

Authors:  K E Pedersen
Journal:  Acta Med Scand Suppl       Date:  1985

6.  P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.

Authors:  Y Chen; A C Pant; S M Simon
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

7.  P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.

Authors:  H Spahn-Langguth; G Baktir; A Radschuweit; A Okyar; B Terhaag; P Ader; A Hanafy; P Langguth
Journal:  Int J Clin Pharmacol Ther       Date:  1998-01       Impact factor: 1.366

8.  In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.

Authors:  M Yamazaki; W E Neway; T Ohe; I Chen; J F Rowe; J H Hochman; M Chiba; J H Lin
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

9.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

Authors:  F Hyafil; C Vergely; P Du Vignaud; T Grand-Perret
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

10.  Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine.

Authors:  H Saitoh; B J Aungst
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

View more
  33 in total

Review 1.  Drug delivery to the small intestine.

Authors:  David R Friend
Journal:  Curr Gastroenterol Rep       Date:  2004-10

Review 2.  Coexistence of passive and carrier-mediated processes in drug transport.

Authors:  Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

3.  Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors.

Authors:  Timo Korjamo; Jukka Mönkkönen; Jouko Uusitalo; Miia Turpeinen; Olavi Pelkonen; Paavo Honkakoski
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

4.  Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine.

Authors:  Michael B Bolger; Viera Lukacova; Walter S Woltosz
Journal:  AAPS J       Date:  2009-05-12       Impact factor: 4.009

5.  P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?

Authors:  Praveen V Balimane; Anthony Marino; Saeho Chong
Journal:  AAPS J       Date:  2008-12-11       Impact factor: 4.009

6.  The asymmetry of the unstirred water layer in permeability experiments.

Authors:  Timo Korjamo; Aki T Heikkinen; Pekka Waltari; Jukka Mönkkönen
Journal:  Pharm Res       Date:  2008-04-16       Impact factor: 4.200

Review 7.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

Review 8.  ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Authors:  M J Zamek-Gliszczynski; C A Lee; A Poirier; J Bentz; X Chu; H Ellens; T Ishikawa; M Jamei; J C Kalvass; S Nagar; K S Pang; K Korzekwa; P W Swaan; M E Taub; P Zhao; A Galetin
Journal:  Clin Pharmacol Ther       Date:  2013-02-25       Impact factor: 6.875

9.  Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers.

Authors:  H M Faessel; A H Burstein; M D Troutman; S A Willavize; K D Rohrbacher; D J Clark
Journal:  Eur J Clin Pharmacol       Date:  2008-07-26       Impact factor: 2.953

10.  An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.

Authors:  Hans Christian Helms; Maria Hersom; Louise Borella Kuhlmann; Lasina Badolo; Carsten Uhd Nielsen; Birger Brodin
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.